# Croma-Pharma GmbH clinical trials: 26 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with Croma-Pharma GmbH as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Croma-Pharma GmbH: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/croma-pharma-gmbh

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931482 | Revitalis - Midface (Cheek Area) | Croma-Pharma GmbH | Not applicable | Recruiting | Skin Smoothness | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931482) |
| November 5, 2026 | NCT07918443 | Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VI | Croma-Pharma GmbH | Not applicable | Not yet recruiting | Moderate to Severe Midface Volume Deficit | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918443) |
| March 25, 2026 | NCT07492277 | A Non-Interventional PMCF Study Evaluating Croma Revitalis for the Correction of Fine Lines | Croma-Pharma GmbH | Observational | Completed | Lateral Canthal Lines (LCL), Perioral Rhytids | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492277) |
| March 16, 2026 | NCT07475455 | Filler Post Market Survey (FIPS) | Croma-Pharma GmbH | Observational | Active not recruiting | Wrinkle Reduction | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475455) |
| November 18, 2023 | NCT06135337 | THIODERM ELATE for Augmentation of Very Thin, Thin, and Moderately Thick Lips | Croma-Pharma GmbH | Not applicable | Completed | Lip Abnormality | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06135337) |
| November 15, 2023 | NCT06133153 | THIODERM ELATE for Volume Augmentation in Lips | Croma-Pharma GmbH | Not applicable | Withdrawn | Lip; Anomaly | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06133153) |
| November 13, 2023 | NCT06128109 | THIODERM STRONG Compared to Juvéderm® VOLUMA® Lidocaine for the Treatment of Midface Volume Deficit | Croma-Pharma GmbH | Not applicable | Completed | Mid Face Volume Deficit | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06128109) |
| May 23, 2022 | NCT05386030 | Saypha® VOLUME Lidocaine for Midface Augmentation | Croma-Pharma GmbH | Phase 3 | Completed | Moderate to Severe Midface Volume Deficit | 562 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05386030) |
| June 8, 2021 | NCT04917588 | Study to Evaluate the Effectiveness, Safety and Long Term Safety of Saypha® FILLER Lidocaine for Lip Augmentation | Croma-Pharma GmbH | Not applicable | Completed | Abnormal Lip | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04917588) |
| May 12, 2021 | NCT04883632 | Saypha® Volume LIdocaine in Nasolabial Folds | Croma-Pharma GmbH | Not applicable | Completed | Moderate to Severe Nasolabial Folds | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04883632) |
| February 21, 2021 | NCT04763265 | Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines | Croma-Pharma GmbH | Phase 2 | Completed | Frown Lines | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04763265) |
| June 19, 2019 | NCT03990883 | Effectiveness and Safety of Princess FILLER Lidocaine in Correction of Nasolabial Folds (NLF) | Croma-Pharma GmbH | Not applicable | Completed | Dermatological Non-Disease | 295 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03990883) |
| June 14, 2019 | NCT03985982 | Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII) | Croma-Pharma GmbH | Phase 3 | Completed | Glabellar Frown Lines | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03985982) |
| April 22, 2019 | NCT03923634 | Princess® RICH for the Correction of Fine Lines | Croma-Pharma GmbH | Not applicable | Completed | Lateral Canthal Lines, Perioral Rhytids | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03923634) |
| August 28, 2018 | NCT03650218 | Safety and Effectiveness of THIODERM STRONG in the Correction of Nasolabial Folds | Croma-Pharma GmbH | Not applicable | Completed | Correction of Nasolabial Folds | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03650218) |
| August 23, 2018 | NCT03644875 | Study of Etacoat in Patients With Cataract Surgery Via the Anterior Chamber | Croma-Pharma GmbH | Observational | Completed | Cataract Surgery | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03644875) |
| August 23, 2018 | NCT03644862 | Study of Etafill in Patients With Cataract Surgery Via the Anterior Chamber | Croma-Pharma GmbH | Observational | Completed | Cataract Surgery | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03644862) |
| August 2, 2018 | NCT03611491 | Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds | Croma-Pharma GmbH | Not applicable | Completed | Correction of Nasolabial Folds | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03611491) |
| May 22, 2018 | NCT03532126 | A 52-week Clinical Investigation of Princess® VOLUME PLUS Lidocaine in Subjects With Midface Volume Deficit | Croma-Pharma GmbH | Observational | Completed | Midface Volume Deficit | 91 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03532126) |
| February 13, 2017 | NCT03050749 | Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars | Croma-Pharma GmbH | Not applicable | Completed | Facial Lipoatrophy, Morphological Asymmetry of the Face, Debilitating Scars | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03050749) |
| February 13, 2017 | NCT03050723 | Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars | Croma-Pharma GmbH | Not applicable | Completed | Facial Lipoatrophy, Morphological Asymmetry of the Face, Debilitating Scars | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03050723) |
| February 13, 2017 | NCT03050710 | Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds | Croma-Pharma GmbH | Not applicable | Completed | Nasolabial Fold, Hypoplastic | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03050710) |
| February 9, 2016 | NCT02677805 | Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II | Croma-Pharma GmbH | Phase 3 | Completed | Glabellar Frown Lines | 251 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02677805) |
| February 9, 2016 | NCT02677298 | Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I | Croma-Pharma GmbH | Phase 3 | Completed | Glabellar Frown Lines | 784 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02677298) |
| June 27, 2013 | NCT01887873 | Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy | Croma-Pharma GmbH | Phase 1 | Completed | Open Angle Glaucoma, Cataract | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01887873) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Not applicable | 15 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Glaucoma, Open-Angle | 1 |
| Cataract | 1 |
| Lymphoid Interstitial Pneumonia | 1 |
| Congenital Abnormalities | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Language schools in the United States](https://specstream.ai/data/businesses/language-schools/united-states)
- [Crane services in the United States](https://specstream.ai/data/businesses/crane-services/united-states)
- [Warehouses in the United States](https://specstream.ai/data/businesses/warehouses/united-states)
- [Outpatient care facilities in the United States](https://specstream.ai/data/businesses/outpatient-care-facilities/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [B2B marketing consultants in the United States](https://specstream.ai/data/businesses/b2b-marketing-consultants/united-states)
